Metabasis Therapeutics Comments On Clinical Results On CS-917 Presented At American Diabetes Association Meeting
SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that four posters and two publications were presented at the 66th scientific sessions of the American Diabetes Association (ADA) in connection with CS-917. The ADA meeting, held June 9-13, 2006 is in Washington, D.C. The posters and publications listed below were given on Sunday, June 11th beginning at 12 noon EDT. CS-917 is a first-in-class, oral product candidate discovered by Metabasis using its proprietary NuMimetic(TM) technology, currently being studied in a Phase IIb human clinical trial for type 2 diabetes. CS-917 is being developed in partnership with Daiichi Sankyo.
The Metabasis presentation was entitled:
* MB06322 (CS-917) Lowers Blood Glucose in Rodents by Inhibiting Both
Hepatic and Renal Gluconeogenesis
The Daiichi Sankyo presentations and publications were as follows:
Presentations:
* Multiple Ascending Doses of CS-917, a Novel Fructose 1,6-bisphosphatase
(FBPase) Inhibitor, in Subjects with Type 2 Diabetes Treated for 14 Days
* Comparison of Acute and Chronic Glucose-Lowering Effect of CS-917, a
Fructose 1,6-bisphosphatase Inhibitor, and Metformin, in Rat Models of
Type 2 Diabetes
* CS-917, a Fructose 1,6-bisphosphatase Inhibitor, Suppresses
Gluconeogenesis In Vitro and In Vivo by a Different Mechanism Than
Metformin
Publications:
* Safety, Tolerability and Pharmacodynamics of Multiple Doses of CS-917 in
Normal Volunteers
* Safety and Tolerability of Single Doses of CS-917, a Novel
Gluconeogenesis Inhibitor, in Normal Male Volunteers
'The study presented at the ADA entailed evaluation of several doses of CS-917 versus placebo given once a day for 14 days to patients with type 2 diabetes. This study demonstrated the potential for CS-917 to lower blood glucose. Subsequent clinical trials have supported the potential for CS-917 to be an important new approach for controlling diabetes and an outpatient Phase IIb trial was initiated earlier this year to establish definitive proof-of- concept,' commented Dr. Paul Laikind, chairman, president, and CEO of Metabasis. 'As noted in this poster, the 14-day, 39 patient clinical trial on CS-917 showed significant post-dose glucose reductions compared to placebo. In addition, CS-917 was well tolerated at all doses. Statistically significant glucose reductions were achieved in three of the four groups despite only about eight patients studied in each group. The ongoing Phase IIb study is measuring the impact on HbA1c levels after three-month dosing. If successful, the trial could support selection of a dose for a pivotal Phase III clinical trial. With an estimated 180 million people worldwide with type 2 diabetes and with incidence continuing to grow, new treatment approaches are urgently needed as current therapies often only achieve modest reduction in the production of glucose. We believe that the inhibition of gluconeogenesis could prove to be an important new therapy to treat this debilitating disease.'
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Forward-Looking Statements:
Statements in this press release that are not strictly historical in nature constitute 'forward-looking statements.' Such statements include, but are not limited to, references to the clinical trial results, further development and potential success of CS-917. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Metabasis' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the progress and timing of clinical trials for Metabasis' product candidates; the fact that positive results from clinical trials does not necessarily mean later clinical trials will succeed; serious adverse side effects of, or serious adverse events related to, Metabasis' product candidates or proprietary technologies; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing Metabasis' product candidates; the potential and progress of preclinical compounds and programs; and other factors discussed in the 'Risk Factors' section of Metabasis' Annual Report on Form 10-Q for the quarter ended March 31, 2006. All forward-looking statements are qualified in their entirety by this cautionary statement. Metabasis is providing this information as of this date of this release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
SOURCE Metabasis Therapeutics, Inc. |
